Here are three things to know.
1. Bristol-Myers will license an experimental drug to Biogen for progressive supranuclear palsy, a rare neurodegenerative brain disorder. The drug may also prove viable for treating Alzheimer’s disease, according to Biogen, which will pay $300 million for the drug.
2. Roche will pay $170 million to receive the licensing rights for Bristol-Myers’ investigational Duchenne muscular dystrophy drug.
3. Bristol-Myers expects the deals to close in the second quarter.
More articles on supply chain:
FDA rejects Eli Lilly’s arthritis drug
Lannett CEO gloats about generic price hikes, investors say
Drug shortages raise price of alternative treatments: 4 study findings
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.